Gene Editing to
Revolutionize Biotech

September 1, 2022

The paper “Dynamic mechanisms of CRISPR interference by Escherichia coli CRISPR-Cas3” was published in Nature Communications.

August 31, 2022

In addition to the current collaborative research and alliance agreement, C4U and Sumitomo Pharma identified additional target cells and genes for two regenerative medicine products respectively, and entered into a collaborative research and alliance agreement for each of them. These brought the total number of our collaborative research and alliance agreement between C4U and Sumitomo Pharma to three.

June 29, 2022

C4U and Logomix have entered into the joint research agreement on applying CRISPR-Cas3 genome editing technology to Logomix's Geno-WritingTM technology.

June 3, 2022

C4U and the Center for iPS Cell Research and Application(CiRA), Kyoto University have conducted a joint research since January 2020 to promote the research utilizing novel genome editing technology over iPS cells.
For the further expansion of this joint research, on May 30, 2022, C4U, CiRA and CiRA Foundation entered into a new collaborative research agreement for the purpose of the "research on genome editing for clinical iPS cells utilizing CRISPR-Cas3 technology".

February 2, 2022

The paper “CRISPR-Cas3-based diagnostics for SARS-CoV-2 and influenza virus” was published in iScience.
For more details, please refer the release by the Institute of Medical Science, the University of Tokyo.

©2019 C4U Corporation